TriangleIMGN853 (NCT03832361)
IMGN853 trial for Endometrial Cancer (NCT03832361). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for women aged eighteen to one hundred with persistent or recurrent, measurable endometrial cancer of specified subtypes. Tumors must express folate receptor alpha. Up to three prior regimens for recurrence are allowed.
The idea: mirvetuximab soravtansine delivers a cell-division-blocking drug to folate-receptor-bearing cells. Patients receive an infusion every three weeks until progression or unacceptable toxicity. Researchers measure tumor response, progression-free survival, and survival. Prior investigational folate-targeted treatment excludes participation.
This phase 2 study plans 50 patients. Alessandro Santin leads at Yale, New Haven, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.